BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Given Average Rating of "Buy" by Brokerages

Key Points

• BlossomHill Therapeutics has a consensus “Buy” rating from five covering analysts, with an average 12-month price target of $32.20. Individual targets range from $28 to $35.
• Insiders made substantial purchases: Directors Carl L. Gordon and Bihua Chen bought $15 million worth of shares combined, while insider purchases over the past three months totaled approximately $25.2 million.
• BLSM shares rose 3.7% to $18.97 in Tuesday trading, remaining between a 52-week range of $15.25 to $20.61.

Shares of BlossomHill Therapeutics, Inc. (NASDAQ:BLSM - Get Free Report) have earned a consensus recommendation of "Buy" from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $32.20.

Several equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of BlossomHill Therapeutics to a "hold" rating in a research note on Saturday, August 15th. Guggenheim assumed coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They issued a "buy" rating and a $30.00 target price on the stock. HC Wainwright initiated coverage on BlossomHill Therapeutics in a report on Tuesday. They set a "buy" rating and a $35.00 price target for the company. Lifesci Capital began coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They issued an "outperform" rating and a $32.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set an "overweight" rating and a $28.00 price objective on the stock.

Insider Activity

In related news, Director Carl L. Gordon purchased 625,000 shares of the business's stock in a transaction dated Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares in the company, valued at approximately $43,428,464. This trade represents a 29.91% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bihua Chen bought 312,500 shares of the company's stock in a transaction on Monday, August 10th. The stock was bought at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the purchase, the director directly owned 3,614,034 shares in the company, valued at approximately $57,824,544. This represents a 9.47% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 1,573,900 shares of company stock valued at $25,181,900.

BlossomHill Therapeutics Trading Up 3.7%

Shares of NASDAQ:BLSM traded up $0.67 during trading on Tuesday, reaching $18.97. 127,422 shares of the stock traded hands, compared to its average volume of 224,464. BlossomHill Therapeutics has a 52-week low of $15.25 and a 52-week high of $20.61.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source